KalVista Pharmaceuticals, Inc.
KALV · NASDAQ
4/30/2025 | 4/30/2024 | 4/30/2023 | 4/30/2022 | |
|---|---|---|---|---|
| Market Cap | $684 | $418 | $247 | $312 |
| - Cash | $99 | $32 | $56 | $31 |
| + Debt | $6 | $7 | $8 | $8 |
| Enterprise Value | $591 | $393 | $199 | $289 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$86 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$173 | -$134 | -$94 | -$81 |
| % Margin | – | – | – | – |
| Net Income | -$183 | -$127 | -$93 | -$82 |
| % Margin | – | – | – | – |
| EPS Diluted | -3.69 | -3.44 | -3.33 | -3.36 |
| % Growth | -7.3% | -3.3% | 0.9% | – |
| Operating Cash Flow | -$153 | -$89 | -$75 | -$78 |
| Capital Expenditures | -$0 | -$0 | -$1 | -$1 |
| Free Cash Flow | -$153 | -$90 | -$76 | -$79 |